{"name":"Matthew Galsky","slug":"matthew-galsky","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1GRjI2cmNieVVHVnBtN0hHU0NyVEFmcEFVYkVxMUxkTEFVczc2UmtZTEhjMzZvZnptSDg2dUE1MDVQTEZDUzJ1eGVnOHRTZFVyT1FsdmVuZGJzdjhQbjdJ?oc=5","date":"2026-02-28","type":"trial","source":"Nature","summary":"A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial - Nature","headline":"A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUURSYUpvWWZtSHdTdlhhMlU3MnE0bTIxWGl1d1dfaWZoWDhfQzh4ZDJ6U00xcEJEaUI4VnFjSXlHMnJPLVFGZENzdjBrb1FRTkRXN0NTbnoxelAxb3d0UDRpelhTWW51czlnTHYxNnBWUjRJV0FJQ0h4cXk0VS1ONDhJWk1BZGxIOUdIZ1NLWTZYczQzQkVweFYzbjdXSjVlMFlPQW9OTEtuTEU?oc=5","date":"2026-02-27","type":"trial","source":"Fierce Pharma","summary":"Padcev-Keytruda combo aces another bladder cancer trial as MIBC landscape becomes more complex - Fierce Pharma","headline":"Padcev-Keytruda combo aces another bladder cancer trial as MIBC landscape becomes more complex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBwVHU1ODV5eDhiZWpwY0dDbGktX2JrS3dGLVRCbXpNNUFZTjhvYnlrYWROaGkxTkFwTk0yNTF0ZkFZUHNGaFZ5WDk0cEllVlE2Yng4?oc=5","date":"2025-12-17","type":"trial","source":"FirstWord Pharma","summary":"Second Phase III success for perioperative Keytruda, Padcev combo in bladder cancer - FirstWord Pharma","headline":"Second Phase III success for perioperative Keytruda, Padcev combo in bladder cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbUg1ZHZLLTVCby1selkyMVlrOU9IUjNIWl9PMEVLbXptUmRWWXJVMXpHd29wWkdfbVNmRi13RlNxNTJneElOZURDRkxkU201d1Nra09QWUFHYUctdlcyb2dEU09pcTNFZFFXVFpVM25mQVRQYUVUaTFpVldJN3hyR0VxVjV0U0l1M1RjdHB1YWFSc1ZDZHhxbzNSSEMyU1h1QkNsRVdSUDVlcC1mM1VzUU1UVWI5NUhQb2Jv?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Pharma","summary":"Keytruda, Padcev keep winning streak with another patient survival benefit in bladder cancer - Fierce Pharma","headline":"Keytruda, Padcev keep winning streak with another patient survival benefit in bladder cancer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-22","type":"regulatory","source":"Medical Dialogues","summary":"USFDA nod to Padcev plus Keytruda for certain patients with bladder cancer: Pfizer, Astellas Pharma - Medical Dialogues","headline":"USFDA nod to Padcev plus Keytruda for certain patients with bladder cancer: Pfizer, Astellas Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQSTZDNzUxZm1ZLWhyTUpwOUdzcllqWWZEaFVtWDNPWFBnTlN5Q0Q2UkFJdDEwVmFFRC01TmFEdjdTSTVDOTRzMmZpYzBPNEE4ejJSZGFjZDFfN0xGcVljcnNRTWljWDNwTlNpY1JFQkNvNDE3UGp6M01jSXItODN6X2tpQ0w1dHVpcDMyOUk4RTR3cHhnQXZKTVNzTTdEaTljS25odEx6YXNVVDluQ3BaN2Jhd3dJYV9tUDNCbg?oc=5","date":"2025-11-21","type":"regulatory","source":"Fierce Pharma","summary":"FDA grants game-changing perioperative approval to Padcev, Keytruda combo in bladder cancer - Fierce Pharma","headline":"FDA grants game-changing perioperative approval to Padcev, Keytruda combo in bladder cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNN1FGWUJJNnZlVmpQOTZiY2ZGSmk1c1JjTmkwbEhrT0dNY1lWZVhrLW5oMzBQT0xSMFFBTFcyLVJjbl9rY2Y3OWt3U04zNndHT3FvcTJzSF93bWNCYVZUUVFCc1RCS0YzV0FSbzRSdDdKV0xrWnlfUS1yamQtV21OZW03V0JyWU1nUGdFQXp3WmdTUnhYTW9Bal9QVC10UQ?oc=5","date":"2025-10-18","type":"trial","source":"Urology Times","summary":"Matthew Galsky, MD, shares 5-year data from CheckMate 274 in MIUC - Urology Times","headline":"Matthew Galsky, MD, shares 5-year data from CheckMate 274 in MIUC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQWHlrUjJUVy0xcnc1Y2hpenAycHppc19GenFrYUszWmxNN01MTGYwT09EeFJiV1FzYVpUNEM4LVJYRlRKZXVSS29INVcyNUpuWTJTQXg5eEhrU3hiWTF3UHllSG9ubnZ2cTFHU0RIVjlWbjU5X0hwa0RiM1N0aERmZkxDbzZhUUVlNmxaWmJUaDcybWtGWEE1Y3IzcktoWG8?oc=5","date":"2025-10-18","type":"trial","source":"Urology Times","summary":"CheckMate 274: 5-year data confirm durable benefit with nivolumab - Urology Times","headline":"CheckMate 274: 5-year data confirm durable benefit with nivolumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQMWZWZXJLTVgwVGlsZTM1aWFGYVQ2N3FmLWJkamNyTjJrQllCSmpia0hxQWNHeEtSRG8zbDJrWk4xMDBTS09QMzBvazh6TFhYZHB2UXJKTzFTdWcyLWhGRUdhbi1aUWJZSU03LXRqamRFbXVNQ3kwXzAyeGYtbFdJLW1FVy11YlZKa3ZjY2czcmJCY0d1eTMyQ1lONDg4aGxmT1dpM2dxalJJUQ?oc=5","date":"2025-10-17","type":"pipeline","source":"CancerNetwork","summary":"Nivolumab Sustains DFS Benefits in Muscle-Invasive Urothelial Carcinoma - CancerNetwork","headline":"Nivolumab Sustains DFS Benefits in Muscle-Invasive Urothelial Carcinoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1UUUpqSDM4MDJsQVRKaVFoUXdhQmhQd3pUQUtLWWFLcE1nclY1VVpIT29ETDEyQWpsS1pVN0FHeV9OUzBUU0trbjZmNTVGNGgxekFHYk55RzRieFlBeW5zRHdCMGdTMHRSdUtYa1JZeXZ0bFVXTzI3bk9HN2stR3M?oc=5","date":"2025-04-07","type":"earnings","source":"Urology Times","summary":"What urologists can expect in Q2 of 2025 - Urology Times","headline":"What urologists can expect in Q2 of 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNeEV4VzhKNGVxQy14OFZfY3lqV05KTmlEWXpQNVV3c0dvM29MMFJqQWZaaXNhSlh5LVJhdkZPU3VFNC16YzZpZ0dPV0Y1R1c4ZGt0dFQ3WGtUNEFSSElQZEZJNHpJNm5ZYmlDT2ZWTm4wLUpKQndyTEJxbmhXcHE3MG90Vy1VNk9vMkVhWXdfWUlNMkozanJoWUxIbGdhVmxybkttUDhhaEpiVXZFMl9iNGJGUXlOOXFVdE1DVFJzTWF3VUU3Snc?oc=5","date":"2024-04-04","type":"pipeline","source":"News-Medical","summary":"Blood-based DNA test spares bladder cancer patients from unnecessary treatments - News-Medical","headline":"Blood-based DNA test spares bladder cancer patients from unnecessary treatments - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1jR3d3RlhIcXVlMUFHc2Nocmh0V0dfYmpHT1Z6NTA5TktaaE11R2pickZNb0VEbE0tcF9mNkEtQWd6RF9ZMk9sS28ySHI4WE5lMjZXa0pZbU5vaDVrLWk4OQ?oc=5","date":"2021-06-02","type":"pipeline","source":"NEJM","summary":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma - NEJM","headline":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}